Integra LifeSciences Holdings Corporation — Form 10-Q Summary
Business Context and Reporting Period
Integra develops, manufactures, and markets medical devices for orthopedic, neurosurgical, reconstructive, peripheral nerve, and surgical-instrument applications. The filing covers the unaudited three months ended March 31, 2011, compared with the three months ended March 31, 2010. The company reports one operating segment.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 | Change |
|---|---|---|---|
| Total revenue | $181.0 million | $172.7 million | +5% |
| Gross profit | $116.1 million | $109.5 million | +6% |
| Gross margin | 64.1% | 63.4% | +70 bps |
| Operating income | $20.9 million | $22.6 million | -8% |
| Operating margin | 11.5% | 13.1% | Down |
| Net income | $11.5 million | $15.2 million | -25% |
| Diluted EPS | $0.38 | $0.50 | -24% |
| Net cash from operating activities | $21.3 million | $28.1 million | -24% |
Revenue by market was $72.2 million for Orthopedics, $68.4 million for Neurosurgery, and $40.4 million for Instruments. International revenue increased 10% to $47.7 million, while U.S. revenue increased 3% to $133.3 million.
Cash and cash equivalents were $104.4 million at March 31, 2011, compared with $128.8 million at December 31, 2010. Working capital was $261.9 million, compared with $243.0 million at year-end 2010.
Total debt included $206.3 million outstanding under the senior credit facility, consisting of $60.0 million of revolving borrowings and $146.3 million of term debt, plus $165.0 million principal amount of 2012 convertible notes. Approximately $390.0 million remained available under the revolving facility. The company was in compliance with its debt covenants.
Capital expenditures were $5.9 million. Financing activities used $44.5 million, including $41.9 million of debt repayments and $4.3 million of share repurchases. The company had no acquisitions during the quarter.
Material Changes Versus the Prior Comparable Period
- Revenue increased $8.3 million, led by Neurosurgery and Instruments, while Orthopedics increased modestly.
- Gross margin improved due primarily to fewer manufacturing variances and increased sales of higher-margin orthopedic products.
- Selling, general and administrative expense increased $7.6 million, primarily from enterprise resource planning implementation, increased international sales and marketing activity, headcount, compensation, and benefits.
- Operating income and net income declined despite revenue growth. Net income was affected by higher operating expenses, increased interest expense, and unfavorable foreign-exchange-related other expense.
- Operating cash flow declined by $6.9 million, mainly because of lower net income and working-capital usage, including a $4.8 million inventory increase.
- Special charges increased to $7.7 million from $3.8 million, including $2.7 million of systems implementation charges, $1.8 million of facility consolidation and transfer charges, and $0.9 million of acquisition-related charges.
- The company repurchased approximately 87,000 shares for $4.3 million under its $75.0 million authorization, leaving $70.7 million available.
Guidance, Outlook, Risks, and Unusual Items
- Management expects 2011 consolidated gross margin to increase over 2010, supported by manufacturing efficiency and a greater mix of higher-margin products.
- Research and development spending is targeted at 6.5% to 7.0% of 2011 revenue. Selling, general and administrative spending, excluding special charges, is expected at 40% to 42% of revenue. Management expects a full-year effective tax rate of approximately 18%.
- Management believes cash and available credit capacity are sufficient for near-term operations, capital expenditures, potential acquisition earn-outs, and other planned uses.
- Spinal hardware sales declined amid a slowdown in the spinal hardware market and increased competition. European healthcare austerity measures may continue to affect demand.
- The company is exposed to foreign-currency risk, particularly involving the euro, Swiss franc, British pound, Canadian dollar, and Australian dollar. There were no foreign-currency hedge contracts outstanding at March 31, 2011.
- An interest-rate swap covered $146.3 million of borrowings and effectively fixed the related interest rate at approximately 4%. The company recognized $0.6 million of additional interest expense from the swap in the quarter.
- The company accrued $3.4 million for a disputed payment related to the former Theken businesses; the seller’s representative alleged that $5.7 million was owed. Product-liability claims had $2.5 million of accruals, offset by a corresponding insurance receivable.
- The company recorded approximately $0.2 million of intangible-asset impairment charges related to discontinued products and rebranding. It also froze benefits under its U.K. pension plan, producing a $0.3 million reduction in projected benefit obligations with no income-statement impact.
- Management states that ordinary-course claims and proceedings are not expected to have a material adverse effect, but acknowledges that contingencies could materially affect results in a particular period.
Important Facts for Investors to Verify
- Whether ERP implementation, restructuring, facility-transfer, and other special charges continue at the elevated Q1 2011 level.
- The sustainability of revenue growth, particularly given weaker spinal hardware demand and competitive pressure.
- Progress toward the projected gross-margin improvement and targeted operating-expense ratios.
- Liquidity and refinancing plans for the $165.0 million convertible notes due in June 2012 and scheduled term-loan repayments.
- The ultimate resolution and cash impact of the disputed Theken earn-out obligation.
- Inventory growth, operating cash-flow conversion, and the allocation of cash between debt repayment, share repurchases, capital expenditures, and acquisitions.
- Foreign-exchange movements, European healthcare spending, and unhedged currency exposure.